

April 16, 2009

Announcement no. 11

Issue of warrants in BioPorto A/S

The Board of Directors of BioPorto A/S has issued warrants to the executive management and the employees as authorized by the Annual General Meeting (AGM) on March 28, 2008. The issued warrants allow for subscription of 483,250 of nominally DKK 3.00 each in BioPorto A/S by cash payment, equal to a nominal value of DKK 1,449,750. The exercise price is set at DKK 3.50.

The Board of Director's decision to issue warrants is a partial utilization of the authorization in article 15 of the Company's articles of association following which the Board of Directors is authorized to issue, on one or more occasions, a number of warrants for shares of nominal value DKK 3.00 corresponding to a maximum of 5% of the Company's nominal capital stock at any given time without any pre-emption right for the present shareholders of the Company.

This issue of 483.250 warrants is equivalent to 1.26% of the nominal capital stock and at an earlier issue 1,427,500 warrants were issued. Thus, a total of 1,910,750 warrants have been issued which is equivalent to 4.99% of the current nominal capital stock. This includes 910,000 warrants issued in 2006 whereof 87,840 are utilized and the remaining 882,160 will lapse unutilized by August 2009 as they were unutilized by the final subscription date April 13, 2009.

The issued warrants are distributed as follows: The executive management is granted 58,200 warrants and the employees of BioPorto A/S and BioPorto Diagnostics A/S are granted 425,050 warrants, all at market price fixed as a weighted average of the listed price in the most recent ten days of trading on Nasdaq OMX Copenhagen prior to the issue on April 16, 2009, yet no less than a minimum price of DKK 3.50. The minimum price of DKK 3.50 applies. A term of maturity of two years is incorporated into the program which means that the warrants granted may at the earliest be exercised on April 16, 2011.

The market value of these 483,250 warrants is calculated to DKK 1,131,670 based on Black-Scholes formula for valuation of warrants.

Gentofte April 16, 2009

The Board of Directors

For further information please contact:

Thea Olesen, CEO

Christina Tønnesen, investor relations

Tel. +45 45 29 00 00, e-mail investor@bioporto.com